Navigation Links
BioWa Announces Expansion of License Agreement with Genentech for BioWa's POTELLIGENT(R) Technology
Date:3/3/2008

PRINCETON, N.J., March 3 /PRNewswire/ -- BioWa, Inc. announced today that it has expanded the license agreement with Genentech, Inc. providing Genentech additional access to BioWa's POTELLIGENT(R) Technology for the research and development of select antibodies for potential therapeutic applications that require enhancement of antibody-dependent cellular cytotoxicity (ADCC).

"BioWa is pleased to extend this license with Genentech, which is a market leader in the field of antibody therapeutics," commented Dr. Masamichi Koike, President and CEO of BioWa. "We feel this alliance will strongly aid in the development of more effective targeted treatments for cancer and other diseases."

Under the terms of the expanded license agreement, BioWa will grant to Genentech commercial rights to research, develop, manufacture and commercialize antibodies utilizing POTELLIGENT(R) Technology for an additional number of targets. In return, BioWa will receive milestone payments and royalties on products developed by Genentech. Additional terms were not disclosed.

About POTELLIGENT(R) Technology

POTELLIGENT(R) Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT(R) Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT(R) Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kogyo Co., Ltd. (TSE: 4151), Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of AccretaMab(TM) platform. AccretaMab(TM) platform consists of POTELLIGENT(R) and COMPLEGENT(TM) Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is offering POTELLIGENT(R) and COMPLEGENT(TM) Technologies to partners under a license to maximize the value of these technologies. In addition, BioWa is focused on development of ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. Both BioWa and Kyowa have POTELLIGENT(R) antibody products at various clinical stages. For more information about BioWa, visit its web site at http://www.biowa.com.

POTELLIGENT(R), COMPLEGENT(TM), and AccretaMab(TM) are the trademarks of Kyowa Hakko Kogyo Co., Ltd. All rights are reserved.


'/>"/>
SOURCE BioWa, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
2. DW Healthcare Partners Announces the Sale of Tandem Labs
3. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
4. Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference
5. MarketResearch.com Announces Distribution of Spectra Intelligence Research
6. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
7. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
8. Wyeth Announces Executive Change in Finance Organization
9. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
10. Pharmacopeia Announces Management Team Changes
11. Reminder Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 10, 2016  Matchbook, Inc., a company specializing ... biotech companies, announced today the appointment of ... Jim brings nearly 25 years of experience in ... spent nearly two decades in executive level roles ... at Genzyme and, most recently headed global logistics ...
(Date:2/10/2016)... , ... February 10, 2016 , ... LATHAM, NEW YORK... ... the SPIE Photonics West conference in San Francisco’s Moscone Center from February ... the same venue. , These latest InGaAs PIN diode standard packages feature a ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... available on Microsoft Azure. On Azure, Arvados provides capabilities for managing and processing ... demand for Microsoft Azure from major institutions collecting and analyzing genomic data,” said ...
(Date:2/10/2016)... ... February 09, 2016 , ... Creation Technologies, leading global provider ... Overall Customer Rating Award from Circuits Assembly , today announced its milestone achievement ... Canada, Mexico and China. , The EMS provider, known in the EMS industry ...
Breaking Biology Technology:
(Date:1/21/2016)... India , January 21, 2016 ... According to a new market research report "Emotion Detection ... and Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020", published by ... is expected to reach USD 22.65 Billion by ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
(Date:1/11/2016)... SAN JOSE, Calif. , Jan. 11, 2016 /PRNewswire/ ... developer of human interface solutions, today announced that its ... display driver integration (TDDI) products won two separate categories ... including Best Mobile Innovator and Best Technology Breakthrough. The ... overall system cost, a simplified supply chain, thinner devices, ...
Breaking Biology News(10 mins):